The FDA has given full approval to Leqembi, a drug that treats early-onset Alzheimer's disease.

The FDA had previously given accelerated approval to the drug.

Medicare and Medicaid can offer broader coverage of the costly treatment which can run patients upwards of $27,000 a year.

News 12 spoke with the Connecticut chapter of the Alzheimer's Association Friday, and they applaud this step forward in the fight against Alzheimer's disease.

"What a study found is that after 1,800 people over 18 months is that this medication was able to reduce cognitive decline by 27% and what that means is more time," said Kristen Cusato, with Alzheimer's Association Connecticut chapter.

The association says it is now up to other insurance companies to follow suit when it comes to covering Leqembi because people are being diagnosed younger nowadays.

They also encourage people to get checked by a doctor if they are having trouble with their memory as early action is important for treatment, especially with this newly approved drug.